Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Chronic Myeloid Leukemia

Trial Information

A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

You have been asked to participate in this study because you have been diagnosed with Philadelphia-chromosome positive chronic myelogenous leukemia (CML) and your disease went into remission (no signs or symptoms of disease) after treatment with Gleevec (Imatinib Mesylate). Despite your response to Gleevec, however, you have residual (a small amount of) leukemia cells that are detectable by more sensitive laboratory tests. The purpose of this study is to find the highest dose of the investigational drug LBH589 that can be given with Gleevec without causing unmanageable side effects. In addition this study will also determine whether combination therapy with LBH589 and Gleevec is effective in reducing or eliminating residual leukemia cells. Your treatment on this study is expected to last 6 months. After your treatment on this study is over, your medical condition will be followed for 3 months.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.